about
Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaUpdate on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer.Cadherin 6 is a new RUNX2 target in TGF-β signalling pathwayCadherin-6 promotes EMT and cancer metastasis by restraining autophagy.Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer.Altered Tnnt3 characterizes selective weakness of fast fibers in mice overexpressing FSHD region gene 1 (FRG1)Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2.Autophagy and epithelial-mesenchymal transition: an intricate interplay in cancer.The extent of whole-genome copy number alterations predicts aggressive features in primary melanomas.Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas.Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN.Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas.High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.TERT Promoter Mutations in Papillary Thyroid Microcarcinomas.TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary thyroid carcinomas with distant metastases.A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases.Role of CBX4 in the Colorectal Carcinoma Metastasis-Letter.Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer TherapyAn Epithelial-to-Mesenchymal Transcriptional Switch Triggers Evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and Identifies Dasatinib as New Therapeutic OptionHDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanismsThe Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells
P50
Q26853261-D3D949D6-83BF-4AA9-B51C-3D93B578F76DQ34152070-BB01BCFA-313E-456B-B0D9-14B79D43142CQ34999638-236D24E1-9E94-42F2-BE1E-FD0D32C603B0Q36067156-9B754D91-5F6D-4976-890A-A7D02B4C7568Q36088722-7FA7EE2A-2EDB-4A2F-8F4C-DE91C407DC64Q37578168-E3B58677-3EAC-4EDE-ACF6-39D788585534Q38391415-119E1DB6-4B83-4E6F-BDA6-16B8034F88ADQ39032755-F2CC0910-BA07-4D4B-AEAF-FABBE0B5A7ABQ40314697-9D43A012-A1F7-4917-8974-0C9BA04C26B2Q42533014-BCC7B589-E7A0-4987-AF60-B6E24633A734Q43490603-D030226E-0B95-4905-9B3D-8771509A7173Q47444118-770F64D0-8AC0-4655-A5D0-0A2C85A5A63FQ47692014-45C46BA5-3193-4D8F-A3B7-230FB214452BQ49197249-14987497-3A97-4E04-AB62-BD1F5F03C25EQ53142928-F89283DD-FF15-42D4-8D94-934ECE1DAC11Q53438816-CE0B69A9-1B7A-4A8C-95D3-4ADD5F2F6903Q54297209-69DA641C-2C1F-4576-97C3-726A4E30B2E8Q54328280-3E09DA35-3C42-435C-BA52-E9B18FF00BB3Q54386381-20F3BCE8-20E1-4F87-B5D5-3E10B7B2A2D1Q54599215-F80B7DFD-0594-41F5-B371-D1609607BE91Q64061318-0889A303-7FA7-4BE3-A15F-55805008D805Q90764277-771948BC-E5F6-4F13-A766-EF9EAB1DCDEFQ92504777-98DC9093-ABA6-48EC-9B69-5396588E8018Q92578198-2BEFD454-1A62-4CF3-BDE4-F82973275861
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Valentina Sancisi
@ast
Valentina Sancisi
@en
Valentina Sancisi
@es
Valentina Sancisi
@nl
Valentina Sancisi
@sl
type
label
Valentina Sancisi
@ast
Valentina Sancisi
@en
Valentina Sancisi
@es
Valentina Sancisi
@nl
Valentina Sancisi
@sl
prefLabel
Valentina Sancisi
@ast
Valentina Sancisi
@en
Valentina Sancisi
@es
Valentina Sancisi
@nl
Valentina Sancisi
@sl
P106
P1153
55356953400
P21
P31
P496
0000-0003-4357-1228